[go: up one dir, main page]

RU2002113755A - High Order Nucleic Acid Structures - Google Patents

High Order Nucleic Acid Structures

Info

Publication number
RU2002113755A
RU2002113755A RU2002113755/04A RU2002113755A RU2002113755A RU 2002113755 A RU2002113755 A RU 2002113755A RU 2002113755/04 A RU2002113755/04 A RU 2002113755/04A RU 2002113755 A RU2002113755 A RU 2002113755A RU 2002113755 A RU2002113755 A RU 2002113755A
Authority
RU
Russia
Prior art keywords
polynucleic acid
structure according
acid structure
nucleic acid
molecules
Prior art date
Application number
RU2002113755/04A
Other languages
Russian (ru)
Inventor
Фрэнк Дж. КЭРР (GB)
Фрэнк Дж. КЭРР
Грэм КАРТЕР (GB)
Грэм КАРТЕР
Original Assignee
Мерк Патент ГмбХ (DE)
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9926810.4A external-priority patent/GB9926810D0/en
Priority claimed from GB0011126A external-priority patent/GB0011126D0/en
Application filed by Мерк Патент ГмбХ (DE), Мерк Патент Гмбх filed Critical Мерк Патент ГмбХ (DE)
Publication of RU2002113755A publication Critical patent/RU2002113755A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (22)

1. Трехмерная полинуклеиновокислотная структура, составленная из множества взаимосвязанных цепочек молекул нуклеиновых кислот или их сегментов при помощи специфического взаимодействия связывания оснований двух или более молекул, отличающаяся тем, что структура не закрыта ковалентно.1. Three-dimensional polynucleic acid structure, composed of many interconnected chains of nucleic acid molecules or their segments using a specific interaction of the binding of the bases of two or more molecules, characterized in that the structure is not closed covalently. 2. Полинуклеиновокислотная структура по п.1, отличающаяся тем, что структура образуется двумя или более нуклеиновокислотными молекулярными цепочками.2. The polynucleic acid structure according to claim 1, characterized in that the structure is formed by two or more nucleic acid molecular chains. 3. Полинуклеиновокислотная структура по п.2, отличающаяся тем, что структура образуется тремя или более нуклеиновокислотными молекулярными цепочками.3. The polynucleic acid structure according to claim 2, characterized in that the structure is formed by three or more nucleic acid molecular chains. 4. Полинуклеиновокислотная структура по любому из пп.1-3, отличающаяся тем, что упомянутая структура представляет собой куб или имеет форму, близкую к кубу.4. Polynucleic acid structure according to any one of claims 1 to 3, characterized in that said structure is a cube or has a shape close to that of a cube. 5. Полинуклеиновокислотная структура по п.3, отличающаяся тем, что кубоидная структура образуется шестью молекулярными цепочками, в которой каждая молекулярная цепочка выступает как отдельная сторона 6-поверхностного куба.5. The polynucleic acid structure according to claim 3, characterized in that the cuboid structure is formed by six molecular chains, in which each molecular chain acts as a separate side of the 6-surface cube. 6. Полинуклеиновокислотная структура по любому из пп.1-5, в которой каждая нуклеиновая последовательность включает два или более домена, которые могут сплавляться с другими молекулами в наборе.6. The polynucleic acid structure according to any one of claims 1 to 5, in which each nucleic sequence includes two or more domains that can be fused with other molecules in the set. 7. Полинуклеиновокислотная структура по п.6, в которой каждая нуклеиновая последовательность включает четыре домена.7. The polynucleic acid structure according to claim 6, in which each nucleic sequence comprises four domains. 8. Полинуклеиновокислотная структура по любому из пп.1-7, в которой упомянутая структура включает молекулы нуклеиновых кислот, которые составляют из участков одноцепочечной нуклеиновой кислоты, разноображенных участками двухцепочечной структуры.8. The polynucleic acid structure according to any one of claims 1 to 7, in which said structure includes nucleic acid molecules that are comprised of single stranded nucleic acid regions that are heterogeneous with double stranded regions. 9. Полинуклеиновокислотная структура по любому из пп.1-8, в которой нуклеиновокислотная цепочка имеет менее 80 нуклеотидов.9. The polynucleic acid structure according to any one of claims 1 to 8, in which the nucleic acid chain has less than 80 nucleotides. 10. Полинуклеиновокислотная структура по п.9, в которой каждая нуклеиновокислотная цепочка имеет менее 50 нуклеотидов.10. The polynucleic acid structure according to claim 9, in which each nucleic acid chain has less than 50 nucleotides. 11. Полинуклеиновокислотная структура по любому из пп.1-10, в которой упомянутая структура имеет конструкцию (А1+В1+С1)+(А2+В2+С2), как изображено на фигуре 1.11. Polynucleic acid structure according to any one of claims 1 to 10, in which said structure has the structure (A1 + B1 + C1) + (A2 + B2 + C2), as shown in figure 1. 12. Полинуклеиновокислотная структура по любому из пп.1-11, в которой упомянутая структура содержит субъединицы, которые составлены из различных произвольных участков последовательностей с целью получения полупроизвольных молекул или их сегментов, способных взаимодействовать с молекулой-мишенью.12. The polynucleic acid structure according to any one of claims 1 to 11, wherein said structure contains subunits that are composed of various arbitrary portions of the sequences in order to obtain semi-arbitrary molecules or their segments capable of interacting with the target molecule. 13. Трехмерная полинуклеиновокислотная структура, которая составлена из множества взаимосвязанных цепочек молекул нуклеиновых кислот или их сегментов при помощи специфического взаимодействия связывания оснований двух или более молекул, где упомянутая структура ковалентно закрыта и содержит субъединицы, которые составлены из различных произвольных участков последовательностей с целью получения полупроизвольных молекул или их сегментов, способных взаимодействовать с молекулой-мишенью.13. Three-dimensional polynucleic acid structure, which is composed of many interconnected chains of nucleic acid molecules or their segments using a specific interaction of the binding of the bases of two or more molecules, where the said structure is covalently closed and contains subunits that are composed of various arbitrary sections of the sequences in order to obtain semi-arbitrary molecules or segments thereof capable of interacting with a target molecule. 14. Полинуклеиновокислотная структура по любому из пп.1-13, в которой варьируются состав и длина последовательностей.14. Polynucleic acid structure according to any one of claims 1 to 13, in which the composition and length of the sequences are varied. 15. Полинуклеиновокислотная структура по п.14, в которой варьируемый состав последовательностей достигается при помощи одной или более модификаций нуклеотидов в рамках последовательности.15. The polynucleic acid structure of claim 14, wherein the variable sequence composition is achieved using one or more nucleotide modifications within the sequence. 16. Полинуклеиновокислотная структура по любому из пп.1-15, в которой упомянутая структура содержит сайты или группы нуклеиновых кислот, которые могут связываться или присоединяться к другой молекуле или твердой матрице.16. The polynucleic acid structure according to any one of claims 1 to 15, in which said structure contains sites or groups of nucleic acids that can bind or attach to another molecule or solid matrix. 17. Полинуклеиновокислотная структура по п.16, в которой упомянутая другая молекула представляет собой протеин, энзим, липопротеин, гликозилированный протеин, иммуноглобулин или их фрагмент.17. The polynucleic acid structure of claim 16, wherein said other molecule is a protein, enzyme, lipoprotein, glycosylated protein, immunoglobulin, or a fragment thereof. 18. Полинуклеиновокислотная структура по п.16, в которой другая молекула представляет собой нуклеиновую кислоту.18. The polynucleic acid structure of claim 16, wherein the other molecule is a nucleic acid. 19. Полинуклеиновокислотная структура, в которой упомянутая молекула фармацевтически эффективна.19. A polynucleic acid structure in which said molecule is pharmaceutically effective. 20. Фармацевтическая композиция, включающая полинуклеиновокислотную структуру по п.19, необязательно совместно с пригодными носителями, эксципиентами и дилуентами и/или другими фармацевтически эффективными соединениями.20. A pharmaceutical composition comprising a polynucleic acid structure according to claim 19, optionally together with suitable carriers, excipients and diluents and / or other pharmaceutically effective compounds. 21. Применение полинуклеиновокислотной структуры по пп.1-18 в качестве диагностического агента.21. The use of polynucleic acid structure according to claims 1 to 18 as a diagnostic agent. 22. Применение полинуклеиновокислотной структуры по п.12 или 13 для составления библиотеки для отражения разнообразия специфически произвольных топологий с целью получения различных функциональностей и/или активностей.22. The use of polynucleic acid structure according to item 12 or 13 for compiling a library to reflect the variety of specifically arbitrary topologies in order to obtain various functionalities and / or activities.
RU2002113755/04A 1999-11-13 2000-11-13 High Order Nucleic Acid Structures RU2002113755A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9926810.4A GB9926810D0 (en) 1999-11-13 1999-11-13 High order nucleic acid-based structures
GB9926810.4 1999-11-13
GB0011126.0 2000-05-10
GB0011126A GB0011126D0 (en) 2000-05-10 2000-05-10 High order nucleic acid-based structures

Publications (1)

Publication Number Publication Date
RU2002113755A true RU2002113755A (en) 2004-01-10

Family

ID=26244234

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002113755/04A RU2002113755A (en) 1999-11-13 2000-11-13 High Order Nucleic Acid Structures

Country Status (16)

Country Link
EP (1) EP1228201A1 (en)
JP (1) JP2003522524A (en)
KR (1) KR20020059727A (en)
CN (1) CN1390253A (en)
AU (1) AU782880B2 (en)
BR (1) BR0015484A (en)
CA (1) CA2391084A1 (en)
CZ (1) CZ20021472A3 (en)
HK (1) HK1052529A1 (en)
HU (1) HUP0203914A2 (en)
MX (1) MXPA02004727A (en)
NO (1) NO20022231L (en)
PL (1) PL358811A1 (en)
RU (1) RU2002113755A (en)
SK (1) SK6042002A3 (en)
WO (1) WO2001036624A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP2739638B1 (en) 2011-08-05 2017-10-04 President and Fellows of Harvard College Compositions and methods relating to nucleic acid nano-and micro-technology
KR20160073936A (en) 2012-07-24 2016-06-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Self-assembly of nucleic acid nanostructures
US9975916B2 (en) 2012-11-06 2018-05-22 President And Fellows Of Harvard College Compositions and methods relating to complex nucleic acid nanostructures
JP2017505104A (en) * 2013-11-08 2017-02-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Nucleic acid nanostructures for in vivo drug delivery
WO2015187390A2 (en) 2014-05-22 2015-12-10 President And Fellows Of Harvard College Scalable nucleic acid-based nanofabrication
EP3967651A1 (en) 2016-03-11 2022-03-16 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
WO2018026880A2 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Crisscross cooperative self-assembly
AU2019302604B2 (en) * 2018-07-12 2023-11-02 Bai Yao Zhi Da (Beijing) Nanobio Technology Co., Ltd. Nucleic acid nanoparticles, pharmaceutical composition comprising same, drug comprising doxorubicin and preparation method thereof
CN110711254B (en) * 2018-07-12 2022-07-26 百药智达（北京）纳米生物技术有限公司 Nucleic acid nanoparticles and pharmaceutical compositions comprising the same
CN110960690B (en) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 Medicine containing epirubicin, preparation method thereof, pharmaceutical composition and application thereof
CN110960534B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing pentafluorouracil, preparation method thereof, pharmaceutical composition and application thereof
CN110960542B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicament containing pirarubicin, preparation method thereof, pharmaceutical composition and application thereof
CN110960530B (en) * 2018-09-30 2022-07-22 百药智达（北京）纳米生物技术有限公司 Tacrine-containing medicine, preparation method thereof, pharmaceutical composition and application thereof
CN110960536B (en) * 2018-09-30 2022-07-26 百药智达（北京）纳米生物技术有限公司 Aspirin-containing medicine, preparation method, pharmaceutical composition and application thereof
CN111053765B (en) * 2018-10-16 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing paclitaxel, preparation method, pharmaceutical composition and application thereof
CN111068065B (en) * 2018-10-22 2022-07-26 百药智达（北京）纳米生物技术有限公司 Drug containing oxaliplatin, preparation method thereof, pharmaceutical composition and application thereof
CN111084887B (en) * 2018-10-23 2022-07-22 百药智达（北京）纳米生物技术有限公司 Flavone-containing medicine, preparation method thereof, medicine composition and application
CN111096965B (en) * 2018-10-29 2022-07-26 百药智达（北京）纳米生物技术有限公司 Medicine containing dihydroartemisinin, preparation method thereof, medicine composition and application thereof
EP3952915A4 (en) 2019-04-10 2023-04-26 President and Fellows of Harvard College Nucleic acid nanostructures crosslinked with oligolysine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151631A1 (en) * 1983-08-03 1985-08-21 The Research Foundation Of State University Of New York Nucleic acid branched junctions with precisely defined migrational mobility
US5386020A (en) * 1991-01-10 1995-01-31 New York University Multiply connected, three-dimensional nucleic acid structures
US5278051A (en) * 1991-12-12 1994-01-11 New York University Construction of geometrical objects from polynucleotides
US6072044A (en) * 1996-04-26 2000-06-06 New York University Nanoconstructions of geometrical objects and lattices from antiparallel nucleic acid double crossover molecules

Also Published As

Publication number Publication date
MXPA02004727A (en) 2002-08-30
HUP0203914A2 (en) 2003-03-28
NO20022231D0 (en) 2002-05-10
JP2003522524A (en) 2003-07-29
AU2000101A (en) 2001-05-30
KR20020059727A (en) 2002-07-13
CN1390253A (en) 2003-01-08
EP1228201A1 (en) 2002-08-07
BR0015484A (en) 2002-07-02
AU782880B2 (en) 2005-09-08
WO2001036624A1 (en) 2001-05-25
PL358811A1 (en) 2004-08-23
CA2391084A1 (en) 2001-05-25
SK6042002A3 (en) 2002-12-03
NO20022231L (en) 2002-05-10
HK1052529A1 (en) 2003-09-19
CZ20021472A3 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
RU2002113755A (en) High Order Nucleic Acid Structures
Seeman Nucleic acid nanostructures and topology
Fu et al. DNA double-crossover molecules
LaBean et al. Construction, analysis, ligation, and self-assembly of DNA triple crossover complexes
Seeman et al. New motifs in DNA nanotechnology
DK2036926T3 (en) SINGLE-CHAIN MOLECULE THAT CAN BIND TO MULTIPLE ANTIGEN, ITS MANUFACTURING AND USE
ATE265488T1 (en) COMBINATIONS FOR INTRODUCING NUCLEIC ACIDS INTO CELLS
JP2002513805A5 (en)
DK1250453T3 (en) Use of multiple recombination sites with unique specificity in recombination cloning
RU93005089A (en) MANUFACTURING HUMAN PROTEIN, DNA, CELL, PHARMACEUTICAL COMPOSITION, USE OF DERIVATIVE PROTEIN C, METHOD OF OBTAINING
Benjamin et al. Geometric arrangements of Tn3 resolvase sites.
EP2017343A3 (en) Protein A based binding domains with desirable activities
Sa-Ardyen et al. Self-assembling DNA graphs
EP1281711A4 (en) COUPLING AGENTS FOR DNA STRANDS AND COMPOUNDS THEREOF
Jonoska et al. Computation by self-assembly of DNA graphs
Goodsell Sequence recognition of DNA by lexitropsins
Wang et al. Structural domains of DNA mesojunctions
US20230073821A1 (en) Antigen-binding proteins targeting coronavirus (cov) variants
Numajiri et al. Asymmetric secondary and tertiary streptavidin/DNA complexes selectively formed in a nanometer-scale DNA well
EP1020467A4 (en) AMIDE COMPOUNDS OF N-ACYLAMINO ACIDS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
Zakrzewska et al. Theoretical studies on the interaction of proteins and nucleic acid: II. The binding of α-helix to B-DNA
KR950704002A (en) FORMATION OF TRIPLE HELIX COMPLEXES USING A NOVEL MOTIF
Carra et al. Formation of AraC-DNA sandwiches
Uhlin The three-dimensional structure of ribonucleotide reductase protein R1 from Escherichia coli.
CN116854785A (en) Site-specifically modified and labeled antiviral peptide cyanovirin N